
Written by a model from the transcript; not yet reviewed.
Alzheimer's research has long been marked by dead ends, controversy, and a lack of effective treatments, but recent developments offer genuine grounds for cautious optimism. Vox senior correspondent Dylan Scott joins the show to discuss what has changed over the past five years, from newly approved medications like lecanumab and donanumab that slow cognitive decline to intriguing correlations with common interventions like the shingles vaccine. They also examine dramatic and unverified experimental surgeries from China that claim to reverse symptoms, exploring both the scientific intrigue and the desperate context of a disease that strips away personal identity.
The discussion highlights the immense emotional and financial toll of Alzheimer's, which currently affects 57 million people worldwide and is projected to triple by 2050. While the new drugs only slow down the disease rather than cure it, and many promising candidates will likely fail, researchers now share a more robust understanding of the disease as a multifaceted condition. Ultimately, the incremental progress represents a major shift from the dark era of a few years ago, providing a stronger foundation for future scientific breakthroughs.
The hosts open the episode with a brief intro and promote TikTok as a source of curious content.
The hosts discuss viral videos of Alzheimer’s patients regaining speech and memory after experimental surgery in China.
Host Noam Hessenfeld interviews Vox correspondent Dylan Scott about recent breakthroughs and the state of Alzheimer’s research.
Scott explains the long history of limited treatment options and the controversial FDA approval of a drug five years ago.
Scott outlines new drugs like lecanumab and donanemab, preventive measures such as the shingles vaccine, and lifestyle factors that may reduce risk.
The conversation turns to the unverified Chinese surgery that creates a brain drain, its promising videos, and the skepticism surrounding it.
Controversial FDA Approval Processstory
The FDA approved a controversial Alzheimer's drug against the advice of its own scientific advisors, causing emotional whiplash for patients and families.
Shift In Alzheimer's Research Hypeinsight
After years of stagnation and false starts, recent breakthroughs in treatments and prevention strategies are giving researchers real hope for the future.
Shingles Vaccine And Brain Healthdata
Scientists found an unexpected association between receiving the shingles vaccine and a reduced risk of developing Alzheimer's disease.
New Drugs Slow Cognitive Declinestrategy
Newly available drugs like lecanumab and donanumab target amyloid plaques to slow down the disease, though they carry risks like brain bleeds.
Surreal Brain Drainage Surgerystory
Videos from China show late-stage Alzheimer's patients dramatically improving after an experimental surgery that drains amyloid plaque.
Staggering Global Dementia Statisticsdata
An estimated 57 million people currently live with dementia worldwide, a number that is expected to triple by 2050 and drive up healthcare costs.
The past few months have been full of Alzheimer's optimism: new ideas that could prevent the disease from taking hold, medications that seem to slow it down, and an experimental surgery that might even be able to reverse its progression. It's a lot of hype. Should we believe it? Guest: Dylan Scott, senior correspondent at Vox To watch this episode on video, find us on Netflix! For show transcripts, go to vox.com/unxtranscripts For more, go to vox.com/unexplainable And please email us! [email protected]We read every email. Support Unexplainable (and get ad-free episodes) by becoming a Vox Member today: vox.com/members Learn more about your ad choices. Visit podcastchoices.com/adchoices
4,885 words · 8 speakers
Page updated · transcript and summary are machine-generated